THERAMetrics and Pierrel Research International AG (PRINT) Announce a Cluster of Clinical Awards from medac GmbH

Stans, Switzerland, April 8, 2014 - THERAMetrics Holding AG (the "Company" - SIX: TMX) proudly announces that its fully-owned Pierrel Research International AG (PRINT) has been selected by medac GmbH, a privately held pharmaceutical company, to conduct its 5-year global clinical phase III trial on its developmental conditioning product with the aim to compare conditioning therapies prior to haematopoietic stem cell transplantation in adult patients with AML or MDS.

In addition medac GmbH has awarded PRINT two phase II paediatric conditioning studies in patients with malignant and non-malignant diseases indicated for allogeneic haematopoietic stem cell transplantation.

PRINT will provide Regulatory Submissions, Clinical Monitoring, Site Management, Project Management and DSUR Submissions.

Pierrel Research Group has more than 20 years' experience as a global full-service Contract Research Organization (CRO) providing drug development services to the pharmaceutical, biotechnology, and medical device industries as well as full IMP services. Approximately 300 clinical staff is strategically located in over 16 offices worldwide, enabling a high level of local expertise to be applied to global clinical trials of all sizes.

Ms. Maxime Stevens, Group CEO of PRINT, commented that PRINTs' "international and highly skilled multidisciplinary teams aim to consistently offer high quality, flexible and cost effective services and solutions across the full spectrum of clinical research and regulatory requirements. The Pierrel Group, through the combination of advanced bio-modelling and science, successfully competes in the current market environment by offering consultancy services for clinical and regulatory development programmes, as well as operational services to effectively conduct global phase I - IV clinical trials, late phase, and Non-Interventional Studies ("NIS"). Our key competitive strengths include our drug discovery bio-mathematical platform (DRR 2.0), which enables companies to repurpose or redirect existing compounds to other indications, and facilitates identifying emerging paths though the patho-physiological indications and symptoms of diseases."

About THERAMetrics
THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland).

For further information please contact
THERAMetrics holding AG
Investor and External Relations
Tel.: +41 79 285 37 81
[email protected]
www.therametrics.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.